Becton Dickinson stock (US0718131099): BDX holds near Wall Street's hold consensus

Becton Dickinson shares were being tracked in the U.S. market on 05/31/2026, with MarketBeat data showing a consensus Hold rating and an average price target of USD 183.64. The stock remained listed on the New York Stock Exchange under ticker BDX, anchoring the name in the United States equity market rather than any takeover or delisting scenario.

The latest market snapshot also came alongside fresh ownership and analyst-related filings in the U.S. on 05/31/2026, including a reported Nomura Asset Management share sale, which added another same-day data point for a stock that continues to draw institutional attention in its home market.

As of: 05/31/2026

By the editorial team - specialized in equity coverage.

Becton Dickinson: core business model

Becton Dickinson makes medical technology used across hospitals, laboratories, and care settings, with recurring demand tied to consumables, diagnostics, and equipment placements.

Chart technicals and 52-week range

On Sunday, the most useful read-through is the stock's trading range and trend context rather than a fresh catalyst, because the available same-day evidence is centered on ownership flow and consensus positioning rather than earnings or guidance. MarketBeat's U.S. market snapshot showed a consensus Hold rating, an average target of USD 183.64, and a recent set of broker updates that included Evercore's move to USD 190.00 from USD 180.00 in a report dated 05/07/2026.

The same U.S. listing context matters for interpretation: Becton Dickinson is still priced and followed as a New York-listed name, so the relevant technical lens is the U.S. session rather than a foreign venue. For German readers, the share may also be followed through local trading platforms, but no verified same-day German venue quote was available in the provided sources.

The absence of a completed take-private or delisting notice in the allowed sources keeps the name in the active-listing category for this coverage cycle, which means price action and institutional positioning remain the main daily variables rather than corporate-action endgames.

Conclusion

Sunday's setup points to a stock that is still defined by U.S. listing status, broker consensus, and institutional activity rather than any completed transaction. With no verified delisting evidence in the allowed sources, Becton Dickinson remains a live large-cap medical technology name whose short-term framing is driven more by market positioning than by structural change.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.